460 — Sihuan Pharmaceutical Holdings Income Statement
0.000.00%
Last trade - 00:00
- HK$4.85bn
- HK$1.47bn
- CNY1.86bn
- 31
- 67
- 47
- 44
R2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,878 | 2,464 | 3,038 | 2,181 | 1,861 |
Cost of Revenue | |||||
Gross Profit | 2,289 | 1,914 | 2,430 | 1,488 | 1,296 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5,285 | 1,677 | 2,266 | 4,012 | 1,699 |
Operating Profit | -2,406 | 787 | 772 | -1,831 | 162 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -2,423 | 766 | 496 | -2,123 | -161 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,713 | 547 | 243 | -2,320 | -258 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -2,753 | 473 | 417 | -1,915 | -54 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2,753 | 473 | 417 | -1,915 | -54 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.014 | 0.042 | 0.048 | -0.101 | -0.008 |
Dividends per Share | |||||
Special Dividends per Share |